The Epstein–Barr virus (EBV) and the pathogenesis of MS
DTEND;TZID=Europe/Zurich:20260424T131500 END:VEVENT BEGIN:VEVENT UID:news1641@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143446 DTSTART;TZID=Europe/Zurich:20260427T121500 SUMMARY:Immunomeeting DESCRIPTION:TBA X-ALT-DESC:TBA
DTEND;TZID=Europe/Zurich:20260427T130000 END:VEVENT BEGIN:VEVENT UID:news1620@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260414T173404 DTSTART;TZID=Europe/Zurich:20260428T121500 SUMMARY:FARO Seminar in Oncology DESCRIPTION:1. Cinja Vecchi - “Effect of anti-obesity drugs on mammary ca ncer progression”\\r\\n2. Laurentz Schuhknecht - “CRISPR meets metabol omics: Accelerating drug discovery by combining genetic and chemical metab olic fingerprinting” X-ALT-DESC:1. Cinja Vecchi - “Effect of anti-obesity drugs on mammary cancer progression”
\n2. Laurentz Schuhknecht - “CRISPR meets me tabolomics: Accelerating drug discovery by combining genetic and chemical metabolic fingerprinting”
\n\n\n DTEND;TZID=Europe/Zurich:20260428T131500 END:VEVENT BEGIN:VEVENT UID:news1721@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260417T130247 DTSTART;TZID=Europe/Zurich:20260429T120000 SUMMARY:Guest Speaker: David Withers - Professor at the University of Oxfor d DESCRIPTION:About the talk:\\r\\nCancers not only evade but actively corrup t the immune response tasked with eliminating them. Solid tumours deploy a range of mechanisms that alter the function\, behaviour\, and fate of cyt otoxic effector lymphocytes\, including CD8+ T cells and NK cells\, there by blunting their ability to kill cancer cells. Although immune checkpoin t blockade has demonstrated the therapeutic potential of restoring intrat umoural effector activity\, durable responses remain restricted to a subse t of patients and tumour types. Broadening and sustaining clinical benefit will require therapeutic strategies that target additional suppressive pa thways alongside enhancement of T cell function. However\, designing such rational combination therapies demands a detailed understanding of how th e tumour and the local tissue environment reprogramme cells across the i mmune landscape.\\r\\nOur research aims to define precisely how immune cel ls are reshaped within tumours\, when these changes occur\, and how they i nfluence anti-tumour immunity. Using tumour implantation in photoconverti ble mice\, we have developed novel labelling strategies that distinguish newly infiltrating cells from those retained in the tissue. This approach enables direct tracking of immune cell fate\, quantification of populatio n turnover\, and real-time analysis of how immune subsets adapt to the tum our microenvironment. Here I will discuss ongoing studies interrogating th e emergence and regulation of myeloid populations within in vivo cancer m odels.\\r\\n\\r\\nAbout the speaker:\\r\\nProf. David Withers studied for a PhD in Immunology at the Institute for Animal Health/University of Brist ol (2000-2004)\, then post-doctoral studies first at the NIH\, Bethesda\, USA (NIAMS)\, then at the University of Birmingham\, UK. In 2011\, David w as awarded a Wellcome Trust Research Career Development Fellowship investi gating the role of innate lymphoid cells in regulating memory T cell respo nses and then a Wellcome Trust Senior Research Fellowship in 2016. Most re cently\, his research has developed to consider the regulation of anti-tum our immunity\, exploiting novel in vivo models and supported by Cancer R esearch UK\, the Cancer Research Institute\, Worldwide Cancer Research and the MRC. In June 2024\, David moved his lab to the NDM Centre for Immuno- Oncology at the University of Oxford. As Professor of Experimental Cancer Immunology\, he leads the Tumour-Immune Cell Dynamics Group\, which is foc used upon understanding how immune cells behave within\, and respond to\, the tumour microenvironment and then what this means for enhancing anti-tu mour T cell responses. The lab is currently supported by a Wellcome Discov ery Award and Cancer Research UK Programme grant. X-ALT-DESC:About the talk:
\nCancers not only eva de but actively corrupt the immune response tasked with eliminating them. Solid tumours deploy a range of mechanisms that alter the function\, behav iour\, and fate of cytotoxic effector lymphocytes\, including CD8+ \;T cells and NK cells\, thereby blunting their ability to kill ca ncer cells. Although \;immune checkpoint blockade&nbs p\;has demonstrated the therapeutic potential of restoring intratumoural e ffector activity\, durable responses remain restricted to a subset of pati ents and tumour types. Broadening and sustaining clinical benefit will req uire therapeutic strategies that target additional suppressive pathways al ongside enhancement of T cell function. However\, designing such rational combination therapies \;demands a detailed understand ing of how the tumour and the local \;tissue environment \;reprogramme cells across the immune landscape.
\nOur resea rch aims to define precisely how immune cells are reshaped within tumours\ , when these changes occur\, and how they influence anti-tumour immunity. Using tumour implantation in \;photoconvertible mice\ , we have developed \;novel labelling strategies \;that distinguish newly infiltrating cells from those retained in the tis sue. This approach enables direct tracking of immune cell fate\, quantific ation of population turnover\, and real-time analysis of how immune subset s adapt to the tumour microenvironment. Here I will discuss ongoing studie s interrogating the \;emergence and regulation of myeloid popu lations within in vivo cancer models.
\n\nAbout the speaker:
\nProf. David Withers studied for a PhD in Immuno logy at the Institute for Animal Health/University of Bristol (2000-2004)\ , then post-doctoral studies first at the NIH\, Bethesda\, USA (NIAMS)\, t hen at the University of Birmingham\, UK. In 2011\, David was awarded a We llcome Trust Research Career Development Fellowship investigating the role of innate lymphoid cells in regulating memory T cell responses and then a Wellcome Trust Senior Research Fellowship in 2016. Most recently\, his re search has developed to consider the regulation of anti-tumour immunity\, exploiting novel \;in vivo \;models and supported by Cancer Research UK\, the Cancer Research Institute\, Worldwide Cancer Research a nd the MRC. In June 2024\, David moved his lab to the NDM Centre f or Immuno-Oncology at the University of Oxford. As Professor of Experimental Cancer Immunology\, he leads the Tumour-Immun e Cell Dynamics Group\, which is focused upon understanding how immune cel ls behave within\, and respond to\, the tumour microenvironment and then w hat this means for enhancing anti-tumour T cell responses. The lab is curr ently supported by a Wellcome Discovery Award and Cancer Research UK Progr amme grant.
DTEND;TZID=Europe/Zurich:20260429T130000 END:VEVENT BEGIN:VEVENT UID:news1708@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260414T173449 DTSTART;TZID=Europe/Zurich:20260429T150000 SUMMARY:PhD Defense DESCRIPTION:The defense will include a public presentation (~30 min) follow ed by a closed examination. Afterwards\, there will be an apéro outside t he ZLF building (if it’s sunny) or in the ZLF 2nd floor coffee room. X-ALT-DESC:The defense will include a public presentation (~30 min) foll owed by a closed examination. Afterwards\, there will be an apéro outside the ZLF building (if it’s sunny) or in the ZLF 2nd floor coffee room. DTEND;TZID=Europe/Zurich:20260429T163000 END:VEVENT BEGIN:VEVENT UID:news1642@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143427 DTSTART;TZID=Europe/Zurich:20260504T121500 SUMMARY:Immunomeeting DESCRIPTION:TBA X-ALT-DESC:
TBA
DTEND;TZID=Europe/Zurich:20260504T130000 END:VEVENT BEGIN:VEVENT UID:news1678@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143417 DTSTART;TZID=Europe/Zurich:20260508T121500 SUMMARY:Genetic Approaches in Biomedical Research DESCRIPTION:Neuronal memory networks: from function to structure X-ALT-DESC:Neuronal memory networks: from function to structure
DTEND;TZID=Europe/Zurich:20260508T131500 END:VEVENT BEGIN:VEVENT UID:news1643@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143404 DTSTART;TZID=Europe/Zurich:20260511T121500 SUMMARY:Immunomeeting DESCRIPTION:TBA X-ALT-DESC:TBA
DTEND;TZID=Europe/Zurich:20260511T130000 END:VEVENT BEGIN:VEVENT UID:news1644@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143351 DTSTART;TZID=Europe/Zurich:20260518T121500 SUMMARY:Immunomeeting DESCRIPTION:TBA X-ALT-DESC:TBA
DTEND;TZID=Europe/Zurich:20260518T130000 END:VEVENT BEGIN:VEVENT UID:news1621@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143339 DTSTART;TZID=Europe/Zurich:20260519T121500 SUMMARY:FARO Seminar in Oncology DESCRIPTION:1. Juan Jaurigui \\r\\n\\r\\n2. Morgan Camille Legall X-ALT-DESC:1. Juan Jaurigui \;
\n\n2. Morgan Camille Legall
DTEND;TZID=Europe/Zurich:20260519T131500 END:VEVENT BEGIN:VEVENT UID:news1658@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143330 DTSTART;TZID=Europe/Zurich:20260520T083000 SUMMARY:OncoDay 2026 DESCRIPTION:This flagship annual event brings together leading academic res earchers\, clinicians\, and biotech / pharmaceutical innovators in the fie ld of Oncology across the Basel area. The Basel OncoDay offers young scien tists a unique platform to showcase their work\, exchange ideas\, and conn ect with experts in the field. X-ALT-DESC:This flagship annual event brings together leading academic r esearchers\, clinicians\, and biotech / pharmaceutical innovators in the f ield of Oncology across the Basel area. The Basel OncoDay offers young sci entists a unique platform to showcase their work\, exchange ideas\, and co nnect with experts in the field.
DTEND;TZID=Europe/Zurich:20260520T170000 END:VEVENT BEGIN:VEVENT UID:news1679@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143319 DTSTART;TZID=Europe/Zurich:20260522T121500 SUMMARY:Genetic Approaches in Biomedical Research DESCRIPTION:Addressing the role of oncogenes and tumor suppressors using mo use models of brain tumors and conditional genetics X-ALT-DESC:Addressing the role of oncogenes and tumor suppressors using mouse models of brain tumors and conditional genetics
DTEND;TZID=Europe/Zurich:20260522T131500 END:VEVENT BEGIN:VEVENT UID:news1680@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143307 DTSTART;TZID=Europe/Zurich:20260529T121500 SUMMARY:Genetic Approaches in Biomedical Research DESCRIPTION:Investigating gene function with in vivo pooled CRISPR screens X-ALT-DESC:Investigating gene function with in vivo pooled CRISPR screen s
DTEND;TZID=Europe/Zurich:20260529T131500 END:VEVENT BEGIN:VEVENT UID:news1645@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143257 DTSTART;TZID=Europe/Zurich:20260601T121500 SUMMARY:Immunomeeting DESCRIPTION:TBA X-ALT-DESC:TBA
DTEND;TZID=Europe/Zurich:20260601T130000 END:VEVENT BEGIN:VEVENT UID:news1646@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143249 DTSTART;TZID=Europe/Zurich:20260608T121500 SUMMARY:Immunomeeting DESCRIPTION:TBA X-ALT-DESC:TBA
DTEND;TZID=Europe/Zurich:20260608T130000 END:VEVENT BEGIN:VEVENT UID:news1722@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260417T131127 DTSTART;TZID=Europe/Zurich:20260608T140000 SUMMARY:Guest Speaker: Thomas Liechti\, PhD - Norwegian Institute of Public Health DESCRIPTION:Please register for the seminar using the QR-Code provided on t he flyer. X-ALT-DESC:Please register for the seminar using the QR-Code pro vided on the flyer.
DTEND;TZID=Europe/Zurich:20260608T150000 END:VEVENT BEGIN:VEVENT UID:news1647@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143238 DTSTART;TZID=Europe/Zurich:20260615T121500 SUMMARY:Immunomeeting DESCRIPTION:TBA X-ALT-DESC:TBA
DTEND;TZID=Europe/Zurich:20260615T130000 END:VEVENT BEGIN:VEVENT UID:news1622@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143228 DTSTART;TZID=Europe/Zurich:20260630T121500 SUMMARY:FARO Seminar in Oncology DESCRIPTION:1. Aryan Kamal\\r\\n\\r\\n2. Lisa Schiess X-ALT-DESC:1. Aryan Kamal
\n\n2. Lisa Schiess
DTEND;TZID=Europe/Zurich:20260630T131500 END:VEVENT BEGIN:VEVENT UID:news1623@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143219 DTSTART;TZID=Europe/Zurich:20260908T121500 SUMMARY:FARO Seminar in Oncology DESCRIPTION:1. Jakob Kerbl-Knapp \\r\\n\\r\\n2. Javioer Parejaromanmisomea bozorg X-ALT-DESC:1. Jakob Kerbl-Knapp \;
\n\n2. Javioer Parejaromanm isomeabozorg
DTEND;TZID=Europe/Zurich:20260908T131500 END:VEVENT BEGIN:VEVENT UID:news1520@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20251220T125135 DTSTART;TZID=Europe/Zurich:20260909T080000 SUMMARY:DBM Summer Symposium 2026 DESCRIPTION:DBM Summer Symposium 2026 X-ALT-DESC:DBM Summer Symposium 2026
DTEND;TZID=Europe/Zurich:20260909T131500 END:VEVENT BEGIN:VEVENT UID:news1685@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143114 DTSTART;TZID=Europe/Zurich:20260911T090000 SUMMARY:Basel Spatial OMICS Symposium DESCRIPTION:Basel Spatial OMICS Symposium [https://spatialomicsnetwork.unib as.ch/en/event/details/second-spatial-omics-network-symposium/]The event w ill feature scientific presentations from academic and industry groups acr oss the Basel area\, including contributions from the University of Basel (Biozentrum\, DBM\, IOB)\, ETH Zurich (D-BSSE)\, Roche\, Novartis\, FMI an d BIIE.\\r\\nRegistration deadline: 4th September\, 2026.\\r\\nRegistratio n is free but required X-ALT-DESC:\nRegistration deadline: < /strong>4th September\, 2026.
\nRegistration is free but required
DTEND;TZID=Europe/Zurich:20260911T183000 END:VEVENT BEGIN:VEVENT UID:news1624@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143204 DTSTART;TZID=Europe/Zurich:20261027T121500 SUMMARY:FARO Seminar in Oncology DESCRIPTION:1. Anna Reisch \\r\\n\\r\\n2. Alessandra Vescovi X-ALT-DESC:1. Anna Reisch \;
\n\n2. Alessandra Vescovi
DTEND;TZID=Europe/Zurich:20261027T131500 END:VEVENT BEGIN:VEVENT UID:news1625@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143151 DTSTART;TZID=Europe/Zurich:20261117T121500 SUMMARY:FARO Seminar in Oncology DESCRIPTION:1. Anne Eugster \\r\\n\\r\\n2. Jerneja Koren X-ALT-DESC:1. Anne Eugster \;
\n\n2. Jerneja Koren
DTEND;TZID=Europe/Zurich:20261117T131500 END:VEVENT BEGIN:VEVENT UID:news1626@biomedizin.unibas.ch DTSTAMP;TZID=Europe/Zurich:20260409T143139 DTSTART;TZID=Europe/Zurich:20261215T121500 SUMMARY:FARO Seminar in Oncology DESCRIPTION:1. Anna Salameroboix \\r\\n\\r\\n2. Timo Schenker X-ALT-DESC:1. Anna Salameroboix \;
\n\n2. Timo Schenker
DTEND;TZID=Europe/Zurich:20261215T131500 END:VEVENT END:VCALENDAR